One in 10 people live with the fear of accidental exposures to things like peanuts, eggs or milk. An EpiPen is always at their side. Now, a Chicago research team says a drug already on the market ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...